Axa
LGND icon

Axa’s Ligand Pharmaceuticals LGND Stock Holding History

Axa’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,358
Closed -$1.51M – 1281
2016
Q2 		$1.51M Buy
+20,358
New +$1.51M 0.01% 790
2016
Q1 		– Sell
-15,870
Closed -$1.07M – 1367
2015
Q4 		$1.07M Buy
+15,870
New +$980K ﹤0.01% 892

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Axa's LGND Position: Q3 2016 in Review

Axa sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 20,358 shares — an estimated $1.51M sold.

Axa first reported a position in LGND in Q4 2015 and held it in 2 quarters. The position peaked at $1.51M in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Axa reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Axa sold 20,358 Ligand Pharmaceuticals shares in Q3 2016, an estimated $1.51M.
  • Axa first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Axa's Ligand Pharmaceuticals position peaked at $1.51M in Q2 2016.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Axa's 13F filing for Q3 2016, filed 10 Nov 2016.